Open Access. Powered by Scholars. Published by Universities.®

Medicine and Health Sciences Commons

Open Access. Powered by Scholars. Published by Universities.®

Pharmaceutical Preparations

PDF

University of North Dakota

Articles 1 - 9 of 9

Full-Text Articles in Medicine and Health Sciences

The Impact Of Medical Marijuana On The Opioid Crisis, Carl David Eastep Jan 2019

The Impact Of Medical Marijuana On The Opioid Crisis, Carl David Eastep

Physician Assistant Scholarly Project Posters

• The opioid crisis dictates the need for research into alternative treatments for acute and chronic pain.

• Comprehensive literature review was conducted to determine if medical marijuana might play a role in the treatment of acute and chronic pain.

• The addiction profiles of medical marijuana and prescription opiates were compared along with the adverse effects and quality of life.

• No use for medical marijuana for the treatment of acute pain.

• Likely some benefits from medical marijuana for chronic pain.

• Addictive profile

• Marijuana – marijuana withdrawal syndrome.
• Prescription Opiates – highly addictive

• Adverse …


Use Of Beta-Antagonists Or Hmg-Coa Reductase Inhibitors For Cardioprotection During Chemotherapy In Oncology Patients, Nicole Streich Jan 2019

Use Of Beta-Antagonists Or Hmg-Coa Reductase Inhibitors For Cardioprotection During Chemotherapy In Oncology Patients, Nicole Streich

Physician Assistant Scholarly Project Posters

Over the years, oncologists are better able to fight cancer and have increased cancer survival, but we are also finding that these lifesaving therapies can affect the heart and other parts of the body in a negative way. Chemotherapy is excellent at destroying cancer cells, but it also causes collateral damage to other healthy cells. There are certain chemotherapeutic agents that are known to cause cardiotoxicity. Currently we are monitoring the heart function of the patients who are receiving these cardiotoxic drugs prior to starting the chemotherapy as well as during and after treatment. However, there are currently no recommendations …


Cannabinoid Therapy In Chronic Pain Management, Breanna Joy Privratsky, Jan 2018

Cannabinoid Therapy In Chronic Pain Management, Breanna Joy Privratsky,

Physician Assistant Scholarly Project Papers

In 1996, the state of California was the first in the union to allow for the use of medical marijuana. Since then, 28 more states have enacted similar laws (National Conference of State Legislatures, [NCSL], 2017). With the ever-growing opiate problem that has now been classified as an epidemic by the Centers for Disease Control and Prevention, medical marijuana could be a viable alternative to this problem. As of 2014, the CDC reported opioid deaths were up 369%, which is more than 91 deaths per day from overdose (Centers for Disease Control, [CDC], 2017). The purpose of this study is …


Cannabinoid Therapy In Chronic Pain Management, Breanna Joy Privratsky Jan 2018

Cannabinoid Therapy In Chronic Pain Management, Breanna Joy Privratsky

Physician Assistant Scholarly Project Posters

In 1996, the state of California was the first in the union to allow for the use of medical marijuana. Since then, 28 more states have enacted similar laws (National Conference of State Legislatures, [NCSL], 2017). With the ever-growing opiate problem that has now been classified as an epidemic by the Centers for Disease Control and Prevention, medical marijuana could be a viable alternative to this problem.

As of 2014, the CDC reported opioid deaths were up 369%, which is more than 91 deaths per day from overdose (Centers for Disease Control, [CDC], 2017). The purpose of this study is …


Metformin And Vitamin B12 Deficiency: Consequences And Patient Monitoring, Kathryn Dietz Jan 2017

Metformin And Vitamin B12 Deficiency: Consequences And Patient Monitoring, Kathryn Dietz

Physician Assistant Scholarly Project Posters

• The incidence of type 2 diabetes has been increasing at a rapid rate in the United States.

• Metformin is recommended as the first line treatment to be started at the time of diagnosis in all patients without contraindications and has been associated with vitamin B12 deficiency.

• There are currently no clinical guidelines for the routine monitoring of B12 levels in this population.

• The purpose of this scholarly project is to determine if there are consequences of this deficiency and to make recommendations for screening patients.

• It includes current research that focuses on the pathophysiology of …


The Association Between Antipsychotic Medication And Weight Gain, Brian Steen Jan 2017

The Association Between Antipsychotic Medication And Weight Gain, Brian Steen

Physician Assistant Scholarly Project Posters

• Antipsychotic medications are utilized for patients with many mental health problems including schizophrenia, attention deficit hyperactivity disorder, autism, bipolar mania, and psychotic depression. The antipsychotic medications treat the symptoms associated with these mental health disorders.

• Antipsychotic medications, while being efficacious to these symptoms, can have unwanted side effects, including weight gain. The purpose of this study was to determine if there is a strong relationship with antipsychotic medication use and weight gain.

• The review of literature was conducted with an online search of Cochrane, PubMed, and PsycInfo for journal articles, research studies, and other scholarly reviews. Articles …


Pharmacogenetic Testing In The Treatment Of Major Depressive Disorder, Brianna Strube Jan 2017

Pharmacogenetic Testing In The Treatment Of Major Depressive Disorder, Brianna Strube

Physician Assistant Scholarly Project Posters

• Major depressive disorder (MDD) is one of the most prevalent psychiatric disorders in the United States and is a large cause of disability. Antidepressants take weeks/months to become effective which can lead to noncompliance. Treatment has a high failure rate which increases medical costs and leads to decreased patient outcomes.

• Pharmacogenetic testing is the practice of analyzing genetic differences to predict a patient’s response to medications to improve efficacy and decrease adverse side effects. The purpose of this study was to investigate if pharmacogenetic-guided treatment, specifically in the use of antidepressants in MDD, has resulted in improved patient …


Association Between Proton Pump Inhibitor Use & Dementia: A Two-Fold Approach, Lisa Steers Jan 2017

Association Between Proton Pump Inhibitor Use & Dementia: A Two-Fold Approach, Lisa Steers

Physician Assistant Scholarly Project Posters

An observational study of data derived from the German Study on Aging, Cognition and Dementia indicated that proton pump inhibitor use was associated with dementia risk (Benmassaoud, McDonald, & Lee, 2016). The purpose of this study is to explore a two-fold approach between proton pump inhibitor use and dementia. This two-fold approach will first investigate the association between dementia and proton pump inhibitor use and secondly, the proposed pathophysiology behind it. This approach to proton pump inhibitor use and dementia will allow for providers to utilize the association and make decisions to avoid chronic proton pump inhibitor use in effort …


Use Of Donepezil In Alzheimer's Disease: Suggested Practice Guidelines, Tamara Berg Jan 2015

Use Of Donepezil In Alzheimer's Disease: Suggested Practice Guidelines, Tamara Berg

Physician Assistant Scholarly Project Posters

Alzheimer’s disease (AD) is the cause of 60-80% of dementia (2014 Alzheimer’s disease, 2014). AD is estimated to affect over 5 million people over age 65 in the US (2014 Alzheimer’s disease, 2014). With the onset of baby boomers reaching the age of 65 and increased longevity it is estimated that 16 million persons will have Alzheimer’s by 2050. Eighty two percent of persons with AD are over age 85. In 2014 AD is the 6th leading cause of death and the highest cost disease in the US. (2014 Alzheimer’s disease, 2014)

The predicted increase in prevalence and incidence of …